Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: A systematic review and meta-analysis

Genetics and Molecular Research

Volumn 14, Issue 3, 2015, Pages 7490-7501

  Xu, H B ^a,c   Wang, H D ^b   Li, C H ^a   Ye, S ^a   Dong, M S ^a   Xia, Q J ^a   Zhang, A Q ^a   Pan, K ^a   Ge, X L ^a   Dong, J H ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c The 211 Hospital of PLA   (China)

Author keywords

Cirrhosis; Meta analysis; Proton pump inhibitor; Spontaneous bacterial peritonitis

Indexed keywords

PROTON PUMP INHIBITOR;

ARTICLE; ASCITES; BACTERIAL INFECTION; BACTERIAL PERITONITIS; HUMAN; INFECTION RISK; LIVER CIRRHOSIS; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; SYSTEMATIC REVIEW (TOPIC); TREATMENT INDICATION; AGED; CHEMICALLY INDUCED; COMPLICATION; DOSE RESPONSE; META ANALYSIS; MIDDLE AGED; PERITONITIS; RISK FACTOR;

AGED; BACTERIAL INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIVER CIRRHOSIS; MIDDLE AGED; PERITONITIS; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 84953716163     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.July.3.25     Document Type: Article

References (37)

1. Aditi A, Crippin JS and Abhishek A (2012). Role of proton pump inhibitors in the development of spontaneous bacterial peritonitis amongst cirrhotics; a retrospective cohort study. Gastroenterology 142: S946.
2. Bajaj JS, Zadvornova Y, Heuman DM, Hafeezullah M, et al. (2009). Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am. J. Gastroenterol. 104: 1130-1134.
3. Bulsiewicz WJ, Scherer JR, Feinglass JM, Howden CW, et al. (2009). Proton pump inhibitor (PPI) use is independently associated with spontaneous bacterial peritonitis (SBP) in cirrhotics with ascites. Gastroenterology 136: A11.
4. Campbell MS, Obstein K, Reddy KR and Yang YX (2008). Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig. Dis. Sci. 53: 394-398.
5. Chang CS, Chen GH, Lien HC and Yeh HZ (1998). Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 28: 1187-1190.
6. Choi EJ, Lee HJ, Kim KO, Lee SH, et al. (2011). Association between acid suppressive therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Scand. J. Gastroenterol. 46: 616-620.
7. Davies HT, Crombie IK and Tavakoli M (1998). When can odds ratios mislead? BMJ 316: 989-991.
8. de Vos M, De Vroey B, Garcia BG, Roy C, et al. (2013). Role of proton pump inhibitors in the occurrence and the prognosis of spontaneous bacterial peritonitis in cirrhotic patients with ascites. Liver Int. 33: 1316-1323.
9. Deshpande A, Pasupuleti V, Thota P, Pant C, et al. (2013). Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J. Gastroenterol. Hepatol. 28: 235-242.
10. Egger M, Davey Smith G, Schneider M and Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
11. European Association for the Study of the Liver (2010). EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J. Hepatol. 53: 397-417.
12. Garcia-Martinez I, Francés R, Zapater P, Giménez P, et al. (2015). Use of proton pump inhibitors decrease cellular oxidative burst in patients with decompensated cirrhosis. J. Gastroenterol. Hepatol. 30: 147-154.
13. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W, et al. (2007). Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 46: 922-938.
14. Ginès P, Cárdenas A, Arroyo V and Rodés J (2004). Management of cirrhosis and ascites. N. Engl. J. Med. 350: 1646-1654.
15. Goel GA, Deshpande A, Lopez R, Hall GS, et al. (2012). Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin. Gastroenterol. Hepatol. 10: 422-427.
16. Herzig SJ, Howell MD, Ngo LH and Marcantonio ER (2009). Acid-suppressive medication use and the risk for hospitalacquired pneumonia. JAMA 301: 2120-2128.
17. Higgins JP, Thompson SG, Deeks JJ and Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
18. Jacobs C, Coss Adame E, Attaluri A, Valestin J, et al. (2013). Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment. Pharmacol. Ther. 37: 1103-1111.
19. Kalaitzakis E and Björnsson E (2008). Inadequate use of proton-pump inhibitors in patients with liver cirrhosis. Eur. J. Gastroenterol. Hepatol. 20: 512-518.
20. Kwon JH, Koh SJ, Kim W, Jung YJ, et al. (2014). Mortality associated with proton pump inhibitors in cirrhotic patients with spontaneous bacterial peritonitis. J. Gastroenterol. Hepatol. 29: 775-781.
21. Leontiadis GI, Sharma VK and Howden CW (2006). Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst. Rev.: CD002094.
22. Linsky A, Gupta K, Lawler EV, Fonda JR, et al. (2010). Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch. Intern. Med. 170: 772-778.
23. Mandorfer M, Bota S, Schwabl P, Bucsics T, et al. (2014). Proton pump inhibitor treatment is neither associated with spontaneous bacterial peritonitis development nor with mortality in cirrhotic patients with ascites. J. Hepatol. 60: S393.
24. Merli M, Lucidi C, Di Gregorio V, Giannelli V, et al. (2014). The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int. 35: 362-369.
25. Min YW, Lim KS, Min BH, Gwak GY, et al. (2014). Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. Aliment. Pharmacol. Ther. 40: 695-704.
26. Miura K, Tanaka A, Yamamoto T, Adachi M, et al. (2014). Proton pump inhibitor use is associated with spontaneous bacterial peritonitis in patients with liver cirrhosis. Intern. Med. 53: 1037-1042.
27. Moher D, Liberati A, Tetzlaff J, Altman DG, et al. (2009). Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med. 6: e1000097.
28. Northup PG, Argo CK and Berg CL (2008). Chronic proton pump inhibitor use is strongly associated with hepatorenal syndrome and spontaneous bacterial peritonitis in cirrhosis patients. Hepatology 48: S325A.
29. O’Leary JG, Reddy KR, Wong F, Kamath PS, et al. (2014). Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 13: 753-759
30. Ratelle M, Perreault S, Villeneuve JP and Tremblay L (2014). Association between proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Can. J. Gastroenterol. Hepatol. 28: 330-334.
31. Ratuapli SK, Ellington TG, O’Neill MT, Umar SB, et al. (2012). Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. Am. J. Gastroenterol. 107: 730-735.
32. Siple JF, Morey JM, Gutman TE, Weinberg KL, et al. (2012). Proton pump inhibitor use and association with spontaneous bacterial peritonitis in patients with cirrhosis and ascites. Ann. Pharmacother. 46: 1413-1418.
33. Terg R, Casciato PC, Garbe C, Cartier M, et al. (2012). Proton pump inhibitor therapy does not increase the incidence of bacterial infection in decompensated cirrhotic patients. A nationwide multicenter, prospective study. Hepatology 56: 255A.
34. Trikudanathan G, Israel J, Cappa J and O’Sullivan DM (2011). Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients - a systematic review and meta-analysis. Int. J. Clin. Pract. 65: 674-678.
35. van Vlerken LG, Huisman EJ, van Hoek B, Renooij W, et al. (2012). Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. Eur. J. Clin. Invest. 42: 760-767.
36. Wells G, Shea B, O’Connell D, Peterson J, et al. (2009). The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed August 2014.
37. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, et al. (2002). Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit. Care Med. 30: 1118-1122.